Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR.

ABSTRACT:

Background

TAVI is a widely accepted treatment for patients with severe aortic stenosis (AS). Despite the adoption of diverse therapies, opportunities remain to develop technologies tailored to provide optimal acute and potential long-term benefits, particularly around haemodynamics, flow and durability.

Aims

We aimed to evaluate the safety and feasibility of the DurAVR transcatheter heart valve (THV), a first-in-class biomimetic valve, in the treatment of patients with symptomatic severe AS.

Methods

This was a first-in-human (FIH), prospective, non-randomised, single-arm, single-centre study. Patients with severe, symptomatic AS of any surgical risk and who were eligible for the DurAVR THV prosthesis were recruited; they were assessed at baseline, 30 days, 6 months,

SUBMITTER: Kodali SK 

PROVIDER: S-EPMC10333917 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature